DVA (DaVita) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is DaVita Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of DaVita is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of DaVita's Risk Assessment

For the Medical Care Facilities subindustry, DaVita's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DaVita's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Risk Assessment distribution charts can be found below:

* The bar in red indicates where DaVita's Risk Assessment falls into.

Save Embed

;

Save Embed

;

DaVita (NYSE:DVA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

DaVita Risk Assessment Related Terms

Thank you for viewing the detailed overview of DaVita's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

0I7E:UK TRL:Germany TRL:Germany DVAI34:Brazil

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.

Executives

Berkshire Hathaway Inc	10 percent owner	3555 FARNAM STREET, OMAHA NE 68131
Javier Rodriguez	officer: Chief Executive Officer, DKC	601 HAWAII ST., EL SEGUNDO CA 90245
Joel Ackerman	officer: Chief Financial Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Michael David Staffieri	officer: Chief Operating Officer, DKC	2000 16TH STREET, DENVER CO 80202
Kathleen Alyce Waters	officer: Chief Legal Officer	C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Barbara J Desoer	director	CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty	officer: Chief Compliance Officer	2000 16TH STREET, DENVER CO 80202
Christopher Michael Berry	officer: Chief Accounting Officer	C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Wendy Lee Schoppert	director	6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale	director
Charles Berg	director, officer: Executive Chair, DMG	48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra	director	1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jason M. Hollar	director	3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price	director	ONE CVS DRIVE, WOONSOCKET RI 02895